NIH PAR · NHLBI · R33
PAR-25-025: NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required)
Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards
The objective of this funding opportunity is to support investigator-initiated, phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. The proposed trial can be single or multisite. Applicants applying for funding under this NOFO should be ready to initiate the clinical trial within the first quarter of the project period. Discussion, submission, and attainment of applicable regulatory (FDA, DSMB, IRB) approvals, and establishment of drug (and placebo, if applicable) supplies, and any necessary third-party agreements should be established by the time of award. If time and support for these and other…
- NOFO number
- PAR-25-025
- Type
- PAR
- Activity code
- R33
- Primary institute
- NHLBI · National Heart, Lung, and Blood Institute
- Clinical trials
- Required
- Posted
- Dec 5, 2024
- Opens
- Jan 3, 2025
- Expires
- Jan 8, 2027
PAR-25-025 due dates
No application due dates remain in the listed cycles. Dates marked * are NIH standard due dates. Check the related notices below for changes NIH made after posting.
| Application Due Date(s) | Renewal / Resubmission / Revision (as allowed) | AIDS - New/Renewal/Resubmission/Revision, as allowed | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
|---|---|---|---|---|---|
| February 03, 2025 | February 03, 2025 | May 07, 2025 * | July 2025 | October 2025 | December 2025 |
| June 04, 2025 | June 04, 2025 | September 07, 2025 * | November 2025 | January 2026 | April 2026 |
| October 02, 2025 | October 02, 2025 | January 07, 2026 * | March 2026 | May 2026 | July 2026 |
| February 03, 2026 | February 03, 2026 | May 07, 2026 * | July 2026 | October 2026 | December 2026 |
| June 04, 2026 | June 04, 2026 | Not Applicable | November 2026 | January 2027 | April 2027 |
| October 02, 2026 | October 02, 2026 | Not Applicable | March 2027 | May 2027 | July 2027 |
Funded projects
NIH RePORTER lists no awards under PAR-25-025 in FY2022–FY2026. Awards usually appear a few months after the first review cycle.
Participating institutes
2 NIH institutes and offices take applications under PAR-25-025. Contact the program officer at the institute that fits your research before applying.
- NHLBI · National Heart, Lung, and Blood Institute
- none
Related notices
Mar 31, 2025 · NOT-OD-24-084
This funding opportunity was updated to align with agency priorities. Carefully reread the full funding opportunity and make any needed adjustments to your application prior to submission.April 4, 2024 - Overview of Grant Application and Review Changes for Due Dates on or after January 25,…
Aug 31, 2022 · NOT-OD-22-198
Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See Notice NOT-OD-22-198.
Aug 5, 2022 · NOT-OD-22-189
Implementation Details for the NIH Data Management and Sharing Policy. See Notice NOT-OD-22-189.
Award terms
- Application types allowed
- NewResubmissionRevision The OER Glossary and the How to Apply Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.
- Award budget
- Application budgets should not exceed 1,515,000 in direct costs per year.
- Project period
- The maximum period is 3 years. The scope of the proposed project should determine the requested project period.   NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.
- Funds available and number of awards
- The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.
Related NOFOs
- Reissue of PAR-24-172.
- Companion NOFOs: PAR-25-026.
Other open NOFOs for R33
- RFA-HL-26-016Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)NHLBI · next due Oct 21, 2026
- RFA-HL-26-017Catalyze: Product Definition for Small Molecules, Biologics and Combination Products - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 Clinical Trials Not Allowed)NHLBI · next due Oct 21, 2026
- RFA-HL-26-018Catalyze: Product Definition for Small Molecules, Biologics, and Combination Products - Preliminary Product/Lead Series Identification and Combination Product Prototype (R33 - Clinical Trial Not Allowed)NHLBI · next due Oct 21, 2026
- RFA-HL-26-019Catalyze Product Definition Medical Device prototype design/testing and disease target identification and assay development (R61/R33 - Clinical Trial Not Allowed)NHLBI · next due Oct 21, 2026
- RFA-HL-26-020Catalyze: Product Definition Medical Device Prototype Optimization (R33 - Clinical Trial Not Allowed)NHLBI · next due Oct 21, 2026
- PAR-27-011Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)NHLBI · next due Feb 1, 2027
About this page
GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.